APA
GYRE icon

American Portfolios Advisors’s Gyre Therapeutics GYRE Stock Holding History

American Portfolios Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$108 Hold
29
– – ﹤0.01% 3483
2022
Q2 		$383 Hold
29
– – ﹤0.01% 3414
2022
Q1 		$142 Hold
29
– – ﹤0.01% 3541
2021
Q4 		$197 Hold
29
– – ﹤0.01% 3463
2021
Q3 		$884 Buy
+29
New +$954 ﹤0.01% 3323

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

American Portfolios Advisors's GYRE Position: Q3 2022 in Review

American Portfolios Advisors held its Gyre Therapeutics (GYRE) position steady in Q3 2022 at 29 shares worth $108. The position accounts for ﹤0.01% of the portfolio, ranked #3483.

American Portfolios Advisors first reported a position in GYRE in Q3 2021 and has held it in 5 quarters since. The position peaked at $884 in Q3 2021. 35 funds tracked by Wall St. Rank hold GYRE as of Q3 2022.

  • American Portfolios Advisors held 29 shares of Gyre Therapeutics worth $108 as of Q3 2022.
  • American Portfolios Advisors left its Gyre Therapeutics share count unchanged in Q3 2022.
  • Gyre Therapeutics made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #3483 holding.
  • American Portfolios Advisors first reported a position in Gyre Therapeutics in Q3 2021 and has held it in 5 quarters since.
  • American Portfolios Advisors's Gyre Therapeutics position peaked at $884 in Q3 2021.
  • 35 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.